In this study, we investigated whether the percentage of circulating PD-1+ IFN-γ+ CD8+ T cell at baseline could be a potential marker to predict early response or progression in patients with NSCLC receiving chemotherapy combined with anti–PD-1 therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.